155 related articles for article (PubMed ID: 37435796)
1. Will the future of pharmacovigilance be more automated?
Salvo F; Micallef J; Lahouegue A; Chouchana L; Létinier L; Faillie JL; Pariente A
Expert Opin Drug Saf; 2023; 22(7):541-548. PubMed ID: 37435796
[TBL] [Abstract][Full Text] [Related]
2. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
[TBL] [Abstract][Full Text] [Related]
4. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
Ball R; Dal Pan G
Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
[TBL] [Abstract][Full Text] [Related]
5. Artificial Intelligence in Pharmacovigilance and COVID-19.
Bhardwaj K; Alam R; Pandeya A; Sharma PK
Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726
[TBL] [Abstract][Full Text] [Related]
6. Intelligent Telehealth in Pharmacovigilance: A Future Perspective.
Edrees H; Song W; Syrowatka A; Simona A; Amato MG; Bates DW
Drug Saf; 2022 May; 45(5):449-458. PubMed ID: 35579810
[TBL] [Abstract][Full Text] [Related]
7. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.
Salas M; Petracek J; Yalamanchili P; Aimer O; Kasthuril D; Dhingra S; Junaid T; Bostic T
Pharmaceut Med; 2022 Oct; 36(5):295-306. PubMed ID: 35904529
[TBL] [Abstract][Full Text] [Related]
8. Artificial Intelligence and the Future of the Drug Safety Professional.
Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence in pharmacovigilance: Do we need explainability?
Hauben M
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1311-1316. PubMed ID: 35747938
[No Abstract] [Full Text] [Related]
10. Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices.
Huysentruyt K; Kjoersvik O; Dobracki P; Savage E; Mishalov E; Cherry M; Leonard E; Taylor R; Patel B; Abatemarco D
Drug Saf; 2021 Mar; 44(3):261-272. PubMed ID: 33523400
[TBL] [Abstract][Full Text] [Related]
11. Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities.
Lewis DJ; McCallum JF
Ther Innov Regul Sci; 2020 Jul; 54(4):888-899. PubMed ID: 32557311
[TBL] [Abstract][Full Text] [Related]
12. Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.
Aronson JK
Drug Saf; 2022 May; 45(5):407-418. PubMed ID: 35579806
[TBL] [Abstract][Full Text] [Related]
13. Drug safety in Africa: a review of systems and resources for pharmacovigilance.
Ndagije HB; Walusimbi D; Atuhaire J; Ampaire S
Expert Opin Drug Saf; 2023; 22(10):891-895. PubMed ID: 37676033
[TBL] [Abstract][Full Text] [Related]
14. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
16. A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches.
De Abreu Ferreira R; Zhong S; Moureaud C; Le MT; Rothstein A; Li X; Wang L; Patwardhan M
Adv Ther; 2024 Jun; 41(6):2435-2445. PubMed ID: 38704799
[TBL] [Abstract][Full Text] [Related]
17. Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective.
Swamy S; Mourya M; Kadhe G; Mane A; Sawant S
Expert Opin Drug Saf; 2015; 14(9):1409-20. PubMed ID: 26292785
[TBL] [Abstract][Full Text] [Related]
18. Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability.
Pinheiro LC; Kurz X
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1308-1310. PubMed ID: 35959980
[No Abstract] [Full Text] [Related]
19. A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting.
Li R; Curtis K; Zaidi ST; Van C; Castelino R
Expert Opin Drug Saf; 2022 Sep; 21(9):1193-1204. PubMed ID: 36031811
[TBL] [Abstract][Full Text] [Related]
20. Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.
Hauben M
Clin Ther; 2023 Feb; 45(2):117-133. PubMed ID: 36732152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
